A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On Tuesday, Stifel analysts reiterated their Buy rating and $37.00 price target for Denali Therapeutics Inc. (NASDAQ: DNLI), following discussions with the company’s executive team.

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided ...

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The $37.00 price target remains unchanged, indicating Stifel’s confidence in the value and potential of Denali’s stock. In other recent news, Denali Therapeutics has made significant strides in ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...